The POUR (Postoperative Urinary Retention) Study (POUR)
Postoperative Urinary Retention
About this trial
This is an interventional treatment trial for Postoperative Urinary Retention focused on measuring Sugammadex
Eligibility Criteria
Inclusion Criteria:
- Over the age of 18
- Undergoing laparoscopic inguinal hernia repair at Carolinas Medical Center by attending surgeons within the Division of Gastrointestinal and Minimally Invasive Surgery
- Unilateral or bilateral inguinal hernia repair; may have concurrent umbilical hernia repair performed
- Agreeable to participation in the study
Exclusion Criteria:
- Patients who are having concurrent ventral or flank hernias repaired at time of operation or are having an inguinal hernia repair along with another operation (e.g.
laparoscopic cholecystectomy)
- End-stage renal disease (Creatinine clearance less than 30)
- Neuromuscular disease
- Prior adverse reactions to Sugammadex
- Patients who do not provide consent for the study
Sites / Locations
- Carolinas Medical CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Sugammadex
Retrospective cohort
Prospective cohort of patients undergoing laparoscopic inguinal hernia repair will receive Sugammadex. Sugammadex will be used for reversal of their neuromuscular blockade. The dosing for Sugammadex is 4mg/kg for a deep reversal and a 2mg/kg for a standard reversal, which will be more common for this study. Sugammadex comes in 200mg/2mL and 500mg/5mL vials. Because of the variability in weight of the patients and the type of reversal needed (deep vs standard), 140 5mL vials will be required.
Retrospective cohort of patients who did not receive Sugammadex